Home·Stocks·ALMS

ALMS

Nasdaq

Alumis Inc.

Basic Materials · Pharmaceutical Preparations

Research view

Fundamentals · SEC EDGAR · FY 2025-12-31

Revenue & Earnings — fiscal year

🔒 price chart needs market-data feed

Revenue history unavailable.

Snapshot

SEC EDGAR · FY 2025-12-31

Revenue$24.1M

Net Income$-243.3M

Gross Profit—

Oper Income$-453.8M

EPS (dil)$-2.86

Rev/sh—

FCF/sh—

Book/sh—

Gross M—

Oper M-1886.9%

Profit M-1011.7%

FCF M-1539.2%

ROE-80.8%

ROA-59.1%

ROIC-208.5%

R&D/Rev1605.0%

Rev Y/Y—

Rev 3Y CAGR—

EPS Y/Y72.4%

EPS 3Y CAGR—

FCF 3Y CAGR—

Payout—

Div/sh—

Shs Chg Y/Y+200%

Current Ratio4.34

Quick Ratio—

Debt/Eq—

Int Coverage—

Net Debt—

Total Debt—

Cash & Eq$91.1M

Total Assets$411.9M

Oper CF$-369.5M

Capex$653,000

Free CF$-370.2M

Buybacks$17,000

Equity$301.3M

Liabilities$110.6M

Shs Outstand—

SectorBasic Materials

🔒 P/E—

🔒 Fwd P/E—

🔒 P/S—

🔒 P/B—

🔒 Market Cap—

🔒 Div Yield—

🔒 52W Range—

🔒 Beta—

40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.

Financials — annual

SEC EDGAR · last 1 FY

USD	FY2025
Revenue	$24.1M
Gross Profit	—
Operating Income	$-453.8M
Net Income	$-243.3M
Diluted EPS	$-2.86
Operating Cash Flow	$-369.5M
Free Cash Flow	$-370.2M

COMMUNITY · $ALMS0 theses

POST YOUR TAKE →

Ask AI about ALMS Build basket with ALMS Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.